Published in Front Immunol on April 21, 2016
The ever-expanding myokinome: discovery challenges and therapeutic implications. Nat Rev Drug Discov (2016) 0.80
Natural Killers Are Made Not Born: How to Exploit NK Cells in Lung Malignancies. Front Immunol (2017) 0.75
Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies. Front Immunol (2016) 0.75
Glatiramer Acetate, Dimethyl Fumarate, and Monomethyl Fumarate Upregulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance Their Chemotaxis and Cytotoxicity. Front Immunol (2016) 0.75
High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology (2016) 0.75
Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment. J Immunol Res (2016) 0.75
Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 0.75
Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles (2017) 0.75
The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10
Functions of natural killer cells. Nat Immunol (2008) 9.88
IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity (1998) 8.29
"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 7.61
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 7.07
Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity (2000) 6.97
Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 6.73
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 5.91
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Self-tolerance of natural killer cells. Nat Rev Immunol (2006) 3.75
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2013) 3.74
The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 3.57
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature (2014) 3.45
NK cell development, homeostasis and function: parallels with CD8⁺ T cells. Nat Rev Immunol (2011) 3.38
Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science (2015) 3.35
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Immune functions encoded by the natural killer gene complex. Nat Rev Immunol (2003) 3.21
Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol (2008) 3.17
Human natural killer cell development. Immunol Rev (2006) 3.14
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet (2000) 3.13
Defective lymphoid development in mice lacking Jak3. Science (1995) 3.04
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol (2002) 2.72
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol (2007) 2.66
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol (2014) 2.59
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature (2010) 2.49
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature (2007) 2.26
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol (2012) 2.25
Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med (1998) 2.07
Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. Elife (2014) 1.97
Functional subsets of mouse natural killer cells. Immunol Rev (2006) 1.95
Development, differentiation, and diversity of innate lymphoid cells. Immunity (2014) 1.87
Complexities of TGF-β targeted cancer therapy. Int J Biol Sci (2012) 1.84
TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2004) 1.83
T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J Exp Med (2014) 1.82
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood (2012) 1.81
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 1.80
SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev (2009) 1.78
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.77
Natural killer cell deficiency. J Allergy Clin Immunol (2013) 1.74
Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol (2004) 1.68
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood (2012) 1.68
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood (2012) 1.67
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ (2013) 1.60
Natural killer cell tolerance licensing and other mechanisms. Adv Immunol (2009) 1.60
Location and cellular stages of natural killer cell development. Trends Immunol (2013) 1.59
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood (2014) 1.58
Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol (2008) 1.58
Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol (2010) 1.58
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Res (2015) 1.56
Natural killer cell biology: an update and future directions. J Allergy Clin Immunol (2013) 1.56
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood (2012) 1.46
Bispecific antibodies. Drug Discov Today (2015) 1.44
Balancing natural killer cell activation through paired receptors. Nat Rev Immunol (2015) 1.44
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol (2009) 1.43
STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-gamma. J Immunol (2000) 1.41
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol (2012) 1.38
Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J Clin Invest (2007) 1.29
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell (2015) 1.27
Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res (2014) 1.27
Regulation and Role of EZH2 in Cancer. Cancer Res Treat (2014) 1.27
Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther (2014) 1.27
NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol (2012) 1.18
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica (2014) 1.17
Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res (2014) 1.17
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol (2015) 1.15
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov (2015) 1.14
Regulation of mouse NK cell development and function by cytokines. Front Immunol (2013) 1.14
Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One (2011) 1.12
Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov (2015) 1.12
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol (2015) 1.11
NK cells regulating T cell responses: mechanisms and outcome. Trends Immunol (2015) 1.09
Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia (2011) 1.06
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat Commun (2014) 1.03
CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep (2013) 1.02
In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2. Eur J Immunol (2010) 1.01
Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother (2011) 1.00
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res (2015) 1.00
Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy. Biomol Ther (Seoul) (2013) 0.99
T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov (2014) 0.93
siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells. Int J Clin Exp Pathol (2013) 0.93
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood (2015) 0.93
Natural killer cell-based therapies. F1000 Med Rep (2011) 0.93
T and NK cells: two sides of tumor immunoevasion. J Transl Med (2013) 0.89
Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. Proc Natl Acad Sci U S A (2015) 0.87
CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation. J Immunol (2015) 0.87
Regulation of murine natural killer cell commitment. Front Immunol (2013) 0.86
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. Oncotarget (2015) 0.85
Chromatin targeting drugs in cancer and immunity. Genes Dev (2013) 0.84
The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15. Immunity (2016) 0.84
The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia (2015) 0.81
Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. Front Oncol (2015) 0.81